Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?

Türkbey, Barış; Shah, Vijay; Pang, Yuxi; Bernardo, Marcelino; Xu, Sheng; Kruecker, Jochen; Locklin, Julia K.; Baccala, Angelo A.; Rastinehad, Ardeshir R.; Merino, María J.; Shih, Joanna H.; Wood, Bradford J.; Pinto, Peter A.; Choyke, Peter L.

doi:10.1148/radiol.10100667

Cited by 363 publications

(283 citation statements)

References 41 publications

Supporting

Mentioning

250

Contrasting

Unclassified

Order By: Relevance

“…AUC values for ADC parameters in discriminating low-from intermediateand high-risk lesions (AUC = 0.821-0.854) also lie within the range of previously reported values for peripheral prostate lesions (Donati et al 2014, Kobus et al 2012, Vargas et al 2011, Turkbey et al 2011, Oto et al 2011, Hambrock et al 2011, Peng et al 2013. One recent study reported a higher value of AUC (0.90) for the median ADC in peripheral zone PCas (Hambrock et al 2011).…”

Section: Discussionsupporting

confidence: 83%

Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness

Vignati¹,

Mazzetti²,

Giannini³

et al. 2015

Phys. Med. Biol.

111

105

View full text Add to dashboard Cite

To explore contrast (C) and homogeneity (H) gray-level co-occurrence matrix texture features on T2-weighted (T2w) Magnetic Resonance (MR) images and apparent diffusion coefficient (ADC) maps for predicting prostate cancer (PCa) aggressiveness, and to compare them with traditional ADC metrics for differentiating low-from intermediate/high-grade PCas.The local Ethics Committee approved this prospective study of 93 patients (median age, 65 years), who underwent 1.5 T multiparametric endorectal MR imaging before prostatectomy. Clinically significant (volume ≥0.5 ml) peripheral tumours were outlined on histological sections, contoured on T2w and ADC images, and their pathological Gleason Score (pGS) was recorded. C, H, and traditional ADC metrics (mean, median, 10th and 25th percentile) were calculated on the largest lesion slice, and correlated with the pGS through the Spearman correlation coefficient. The area under the receiver operating characteristic curve (AUC) assessed how parameters differentiate pGS = 6 from pGS ≥ 7.The

show abstract

Section: Discussionsupporting

confidence: 83%

Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness

Vignati¹,

Mazzetti²,

Giannini³

et al. 2015

Phys. Med. Biol.

111

105

View full text Add to dashboard Cite

show abstract

“…Although there are strong inverse correlations between ADC and Gleason grade, mpMRI cannot at this time be considered a replacement for biopsy. 58,59 Nevertheless, ADC values can provide useful information in stratifying patient risk prior to biopsy. For instance, a lesion with very low ADC values that is read as a low-grade tumor on biopsy should be considered for rebiopsy based on the high risk of such a lesion harboring a higher-grade tumor.…”

Section: Multiparametric Mri In Active Surveillancementioning

confidence: 99%

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Tosoian¹,

Loeb²,

Epstein³

et al. 2016

American Society of Clinical Oncology Educational Book

Self Cite

View full text Add to dashboard Cite

Active surveillance (AS) has emerged as a standard management option for men with very low-risk and low-risk prostate cancer, and contemporary data indicate that use of AS is increasing in the United States and abroad. In the favorable-risk population, reports from multiple prospective cohorts indicate a less than 1% likelihood of metastatic disease and prostate cancer-specific mortality over intermediate-term follow-up (median 5 to 6 years). Higher-risk men participating in AS appear to be at increased risk of adverse outcomes, but these populations have not been adequately studied to this point. Although monitoring on AS largely relies on serial prostate biopsy, a procedure associated with significant morbidity, there is a need for improved diagnostic tools for patient selection and monitoring. Revisions from the 2014 International Society of Urologic Pathology consensus conference have yielded a more intuitive reporting system and detailed reporting of low-intermediate grade tumors, which should facilitate the practice of AS. Meanwhile, emerging modalities such as multiparametric magnetic resonance imaging and tissue-based molecular testing have shown prognostic value in some populations. At this time, however, these instruments have not been sufficiently studied to consider their routine, standardized use in the AS setting. Future studies should seek to identify those platforms most informative in the AS population and propose a strategy by which promising diagnostic tools can be safely and efficiently incorporated into clinical practice.

show abstract

“…It was able to be shown that the ADC value has a negative correlation with the Gleason score, i. e., low ADC values are seen primarily in high-grade aggressive prostate cancers [15,18]. Results regarding the ability to differentiate low-grade tumors (Gleason score 3 + 3 = 6) and high-grade tumors (Gleason score > 4 + 3 = 7) in the peripheral zone are very promising since they may be able to help to better determine patient risk potential [19,20]. However since there can still be relevant overlapping of the ADC values in the different Gleason groups, additional studies are needed to implement this grading potential of diffusion-weighted imaging in the clinical routine.…”

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

Multiparametric Magnetic Resonance Imaging in the Detection of Prostate Cancer

Durmus

Baur

Hamm

2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!Prostate cancer is the most common malignancy in men, but only about 10 % of patients die from that cancer. Recent studies suggest that not all patients benefit from a radical therapeutic approach. When prostate cancer is suspected, magnetic resonance imaging (MRI) can make an important contribution to cancer localization within the prostate. Many studies show that T2-weighted morphologic imaging should be supplemented by multiparametric MRI techniques including diffusion-weighted imaging, contrast-enhanced sequences, and MR spectroscopy. This approach detects aggressive prostate cancer with high sensitivity and specificity. The findings of multiparametric MRI additionally contribute information to the assessment of cancer aggressiveness. The use of these multiparametric MRI techniques will gain an increasing role in the clinical management of prostate cancer patients. They can help in establishing a definitive diagnosis with a minimum of invasiveness and may also contribute to optimal individualized treatment. This review article presents the different techniques of multiparametric MRI and discusses their contribution to the detection of prostate cancer. Moreover, this review outlines an objective approach to image interpretation and structured reporting of MRI findings using the PI-RADS criteria. The review concludes with an outline of approaches to prostate biopsy on the basis of MRI (transrectal ultrasound, direct MRI guidance of tissue sampling, and MRI-ultrasound fusion biopsy) and emerging future uses of MRI in the planning of focal treatment options and in the active surveillance of patients diagnosed with prostate cancer.Citation Format:

show abstract

Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?

Cited by 363 publications

References 41 publications

Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness

Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Multiparametric Magnetic Resonance Imaging in the Detection of Prostate Cancer

Contact Info

Product

Resources

About